{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:12:58Z","timestamp":1792141978447,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T00:00:00Z","timestamp":1745452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recent findings indicate that infants with spinal muscular atrophy (SMA) treated early through newborn screening (NBS) have better outcomes. This study aimed to investigate the long-term outcomes of a 5-year SMA NBS program in Taiwan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From September 2017 to August 2022, two NBS centers screened patients for\n                      <jats:italic>SMN1<\/jats:italic>\n                      homozygous deletion using quantitative real-time polymerase chain reaction (RT-PCR) or the Sequenom MassARRAY platform and subsequently confirmed the findings using multiplex ligation-dependent probe amplification (MLPA). Implementation of SMA NBS using RT-PCR or MassARRAY platform efficiently led to the detection of neonates with homozygous survival motor neuron 1 (\n                      <jats:italic>SMN1<\/jats:italic>\n                      ) deletions at a median age of 9 (range 4\u201314) days. Among the 446,966 newborns screened, 22 were detected to have a homozygous deletion of\n                      <jats:italic>SMN1,<\/jats:italic>\n                      followed by MLPA confirmation. One patient initially showed negative screening results but was later confirmed to have a compound heterozygous mutation. Among the 23 confirmed cases, 8 patients had two\n                      <jats:italic>SMN2<\/jats:italic>\n                      copies (all classified as SMA type 1), 11 patients had three\n                      <jats:italic>SMN2<\/jats:italic>\n                      copies (including 4 with SMA type 1, 2 with SMA type 2, 3 with SMA type 3, and 2 asymptomatic cases), and 4 patients had four\n                      <jats:italic>SMN2<\/jats:italic>\n                      copies (all asymptomatic). The mean (median) follow-up duration for 19 survivors was 4.2 (5.0) years. All patients with two\n                      <jats:italic>SMN2<\/jats:italic>\n                      copies developed symptoms within 62 days; those with three\n                      <jats:italic>SMN2<\/jats:italic>\n                      copies experienced disease onset within 1\u00a0year. After diagnosis, most patients were on a watch and wait to receive disease-modifying therapy (DMT) due to initial lack of insurance coverage and limitations on indications after coverage was granted. Of the 19 children who received DMT, the outcomes included 12 walkers, 1 walker requiring support, 3 sitters, 1 non-sitter, and 2 patients with SMA type 1b with two\n                      <jats:italic>SMN2<\/jats:italic>\n                      copies who succumbed to acute respiratory failure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This 5-year SMA NBS study using RT-PCR or the MassARRAY platform, along with an extended follow-up, demonstrates that early diagnosis and prompt treatment can enhance SMA clinical outcomes and change its natural progression in the therapeutic era. Infants with NBS who received presymptomatic DMT had better clinical outcomes than those who received symptomatic DMT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-025-03697-1","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T09:41:16Z","timestamp":1745487676000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Newborn screening facilitates early theranostics and improved spinal muscular atrophy outcome: five-year real-world evidence from Taiwan"],"prefix":"10.1186","volume":"20","author":[{"given":"Chen-Hua","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Rong","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Jun","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Tso","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chen","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inn-Chi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-Jan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Min","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Chen","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dau-Ming","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwang-Jen","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Yuh","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1735-1101","authenticated-orcid":false,"given":"Yuh-Jyh","family":"Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,24]]},"reference":[{"issue":"1","key":"3697_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","volume":"80","author":"S Lefebvre","year":"1995","unstructured":"Lefebvre S, Burglen L, Reboullet S, Clermont O, Burlet P, Viollet L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155\u201365.","journal-title":"Cell"},{"issue":"4","key":"3697_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831\u201346.","journal-title":"Neurol Clin"},{"issue":"8","key":"3697_CR3","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1177\/0883073807305673","volume":"22","author":"BS Russman","year":"2007","unstructured":"Russman BS. Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol. 2007;22(8):946\u201351.","journal-title":"J Child Neurol"},{"issue":"6","key":"3697_CR4","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.ejpn.2018.08.009","volume":"22","author":"EF Tizzano","year":"2018","unstructured":"Tizzano EF, Zafeiriou D. Prenatal aspects in spinal muscular atrophy: from early detection to early presymptomatic intervention. Eur J Paediatr Neurol. 2018;22(6):944\u201350.","journal-title":"Eur J Paediatr Neurol"},{"issue":"7","key":"3697_CR5","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/genes14071377","volume":"14","author":"K Aragon-Gawinska","year":"2023","unstructured":"Aragon-Gawinska K, Mouraux C, Dangouloff T, Servais L. Spinal muscular atrophy treatment in patients identified by newborn screening-a systematic review. Genes. 2023;14(7):1377.","journal-title":"Genes"},{"issue":"124\u20139","key":"3697_CR6","volume":"190","author":"YH Chien","year":"2017","unstructured":"Chien YH, Chiang SC, Weng WC, Lee NC, Lin CJ, Hsieh WS, et al. Presymptomatic diagnosis of spinal muscular atrophy through newborn screening. J Pediatr. 2017;190(124\u20139): e1.","journal-title":"J Pediatr"},{"issue":"2","key":"3697_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017067","volume":"6","author":"YN Su","year":"2011","unstructured":"Su YN, Hung CC, Lin SY, Chen FY, Chern JP, Tsai C, et al. Carrier screening for spinal muscular atrophy (SMA) in 107,611 pregnant women during the period 2005\u20132009: a prospective population-based cohort study. PLoS ONE. 2011;6(2): e17067.","journal-title":"PLoS ONE"},{"issue":"11","key":"3697_CR8","doi-asserted-by":"publisher","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","volume":"96","author":"CL Lorson","year":"1999","unstructured":"Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999;96(11):6307\u201311.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3697_CR9","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1086\/338627","volume":"70","author":"M Feldkotter","year":"2002","unstructured":"Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002;70(2):358\u201368.","journal-title":"Am J Hum Genet"},{"issue":"3","key":"3697_CR10","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.nmd.2018.01.003","volume":"28","author":"M Calucho","year":"2018","unstructured":"Calucho M, Bernal S, Al\u00edas L, March F, Vencesl\u00e1 A, Rodr\u00edguez-\u00c1lvarez FJ, et al. Correlation between SMA type and SMN2 copy number revisited: an analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul Disord. 2018;28(3):208\u201315.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"3697_CR11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers. 2022;8(1):52.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"3697_CR12","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/cpt.2247","volume":"110","author":"G Baranello","year":"2021","unstructured":"Baranello G, Gorni K, Daigl M, Kotzeva A, Evans R, Hawkins N, et al. Prognostic factors and treatment-effect modifiers in spinal muscular atrophy. Clin Pharmacol Ther. 2021;110(6):1435\u201354.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3697_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/ijns10030056","volume":"10","author":"K Cooper","year":"2024","unstructured":"Cooper K, Nalbant G, Sutton A, Harnan S, Thokala P, Chilcott J, et al. Systematic review of presymptomatic treatment for spinal muscular atrophy. Int J Neonatal Screen. 2024;10(3):56.","journal-title":"Int J Neonatal Screen."},{"issue":"2","key":"3697_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3233\/JND-180304","volume":"5","author":"J Glascock","year":"2018","unstructured":"Glascock J, Sampson J, Haidet-Phillips A, Connolly A, Darras B, Day J, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. J Neuromuscul Dis. 2018;5(2):145\u201358.","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"3697_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3233\/JND-190468","volume":"7","author":"J Glascock","year":"2020","unstructured":"Glascock J, Sampson J, Connolly AM, Darras BT, Day JW, Finkel R, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. J Neuromuscul Dis. 2020;7(2):97\u2013100.","journal-title":"J Neuromuscul Dis"},{"issue":"6","key":"3697_CR16","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1177\/22143602241288095","volume":"11","author":"E Vr\u0161\u010daj","year":"2024","unstructured":"Vr\u0161\u010daj E, Dangouloff Y, Osredkar D, Servais L. Newborn screening programs for spinal muscular atrophy worldwide in 2023. J Neuromuscul Dis. 2024;11(6):1180\u20139.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"3697_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/humu.10221","volume":"22","author":"D Anhuf","year":"2003","unstructured":"Anhuf D, Eggermann T, Rudnik-Schoneborn S, Zerres K. Determination of SMN1 and SMN2 copy number using TaqMan technology. Hum Mutat. 2003;22(1):74\u20138.","journal-title":"Hum Mutat"},{"issue":"3","key":"3697_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1373\/clinchem.2005.061192","volume":"52","author":"HY Kao","year":"2006","unstructured":"Kao HY, Su YN, Liao HK, Liu MS, Chen YJ. Determination of SMN1\/SMN2 gene dosage by a quantitative genotyping platform combining capillary electrophoresis and MALDI-TOF mass spectrometry. Clin Chem. 2006;52(3):361\u20139.","journal-title":"Clin Chem"},{"issue":"4","key":"3697_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.ymgme.2014.02.004","volume":"111","author":"SH Lee","year":"2014","unstructured":"Lee SH, Li CF, Lin HY, Lin CH, Liu HC, Tsai SF, et al. High-throughput detection of common sequence variations of Fabry disease in Taiwan using DNA mass spectrometry. Mol Genet Metab. 2014;111(4):507\u201312.","journal-title":"Mol Genet Metab"},{"issue":"3","key":"3697_CR20","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10654-004-6517-4","volume":"20","author":"B Begaud","year":"2005","unstructured":"Begaud B, Martin K, Abouelfath A, Tubert-Bitter P, Moore N, Moride Y. An easy to use method to approximate Poisson confidence limits. Eur J Epidemiol. 2005;20(3):213\u20136.","journal-title":"Eur J Epidemiol"},{"issue":"3","key":"3697_CR21","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/09296174.2013.799918","volume":"20","author":"S Wallis","year":"2013","unstructured":"Wallis S. Binomial confidence intervals and contingency tests: mathematical fundamentals and the evaluation of alternative methods. J Quant Linguist. 2013;20(3):178\u2013208.","journal-title":"J Quant Linguist"},{"issue":"1","key":"3697_CR22","first-page":"2","volume":"60","author":"S Gabriel","year":"2009","unstructured":"Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. 2009;60(1):2\u201312.","journal-title":"Curr Protoc Hum Genet."},{"issue":"1","key":"3697_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000200224","volume":"14","author":"VD Armengol","year":"2024","unstructured":"Armengol VD, Darras BT, Abulaban AA, Alshehri A, Barisic N, Ben-Omran T, et al. Life-saving treatments for spinal muscular atrophy: global access and availability. Neurol Clin Pract. 2024;14(1): e200224.","journal-title":"Neurol Clin Pract"},{"key":"3697_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D\u2019Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"3697_CR25","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137.","journal-title":"Neurology"},{"issue":"1","key":"3697_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.braindev.2020.07.012","volume":"43","author":"SF Ou","year":"2021","unstructured":"Ou SF, Ho CS, Lee WT, Lin KL, Jones CC, Jong YJ, et al. Natural history in spinal muscular atrophy type I in Taiwanese population: a longitudinal study. Brain Dev. 2021;43(1):127\u201334.","journal-title":"Brain Dev"},{"issue":"18","key":"3697_CR27","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"11","key":"3697_CR28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0883073820928784","volume":"35","author":"SE Matesanz","year":"2020","unstructured":"Matesanz SE, Curry C, Gross B, Rubin AI, Linn R, Yum SW, et al. Clinical course in a patient with spinal muscular atrophy type 0 treated with nusinersen and onasemnogene abeparvovec. J Child Neurol. 2020;35(11):717\u201323.","journal-title":"J Child Neurol"},{"issue":"10","key":"3697_CR29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.nmd.2017.05.011","volume":"27","author":"EF Tizzano","year":"2017","unstructured":"Tizzano EF, Finkel RS. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. Neuromuscul Disord. 2017;27(10):883\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"14","key":"3697_CR30","doi-asserted-by":"publisher","first-page":"e1527","DOI":"10.1212\/WNL.0000000000200986","volume":"99","author":"BH Lee","year":"2022","unstructured":"Lee BH, Deng S, Chiriboga CA, Kay DM, Irumudomon O, Laureta E, et al. Newborn screening for spinal muscular atrophy in New York state: clinical outcomes from the first 3 years. Neurology. 2022;99(14):e1527\u201337.","journal-title":"Neurology"},{"issue":"3","key":"3697_CR31","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/jgc4.1549","volume":"31","author":"B Zettler","year":"2022","unstructured":"Zettler B, Estrella E, Liaquat K, Lichten L. Evolving approaches to prenatal genetic counseling for Spinal Muscular Atrophy in the new treatment era. J Genet Couns. 2022;31(3):803\u201314.","journal-title":"J Genet Couns"},{"issue":"6","key":"3697_CR32","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1001\/jamapediatrics.2024.0492","volume":"178","author":"O Schwartz","year":"2024","unstructured":"Schwartz O, Vill K, Pfaffenlehner M, Behrens M, Weiss C, Johannsen J, et al. Clinical effectiveness of newborn screening for spinal muscular atrophy: a nonrandomized controlled trial. JAMA Pediatr. 2024;178(6):540\u20137.","journal-title":"JAMA Pediatr"},{"issue":"11","key":"3697_CR33","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.nmd.2019.09.007","volume":"29","author":"DC De Vivo","year":"2019","unstructured":"De Vivo DC, Bertini E, Swoboda KJ, Hwu WL, Crawford TO, Finkel RS, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842\u201356.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"3697_CR34","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41591-022-01866-4","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1381\u20139.","journal-title":"Nat Med"},{"issue":"7","key":"3697_CR35","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial. Nat Med. 2022;28(7):1390\u20137.","journal-title":"Nat Med"},{"issue":"2","key":"3697_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27853","volume":"68","author":"TO Crawford","year":"2023","unstructured":"Crawford TO, Swoboda KJ, De Vivo DC, Bertini E, Hwu WL, Finkel RS, et al. Continued benefit of nusinersen initiated in the presymptomatic stage of spinal muscular atrophy: 5-year update of the NURTURE study. Muscle Nerve. 2023;68(2):157\u201370.","journal-title":"Muscle Nerve"},{"issue":"9","key":"3697_CR37","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1136\/jnnp-2017-317412","volume":"89","author":"MA Farrar","year":"2018","unstructured":"Farrar MA, Teoh HL, Carey KA, Cairns A, Forbes R, Herbert K, et al. Nusinersen for SMA: expanded access programme. J Neurol Neurosurg Psychiatry. 2018;89(9):937\u201342.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"3697_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S2352-4642(22)00342-X","volume":"7","author":"DS Kariyawasam","year":"2023","unstructured":"Kariyawasam DS, D\u2019Silva AM, Sampaio H, Briggs N, Herbert K, Wiley V, et al. Newborn screening for spinal muscular atrophy in Australia: a non-randomised cohort study. Lancet Child Adolesc Health. 2023;7(3):159\u201370.","journal-title":"Lancet Child Adolesc Health"},{"issue":"12","key":"3697_CR39","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/jnnp-2021-326344","volume":"92","author":"ST Shih","year":"2021","unstructured":"Shih ST, Farrar MA, Wiley V, Chambers G. Newborn screening for spinal muscular atrophy with disease-modifying therapies: a cost-effectiveness analysis. J Neurol Neurosurg Psychiatry. 2021;92(12):1296\u2013304.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3697_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.nmd.2023.11.013","volume":"34","author":"T Dangouloff","year":"2024","unstructured":"Dangouloff T, Thokala P, Stevenson MD, Deconinck N, D\u2019Amico A, Daron A, et al. Cost-effectiveness of spinal muscular atrophy newborn screening based on real-world data in Belgium. Neuromuscul Disord. 2024;34:61\u20137.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"3697_CR41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/dmcn.15286","volume":"65","author":"T Dangouloff","year":"2023","unstructured":"Dangouloff T, Hiligsmann M, Deconinck N, D\u2019Amico A, Seferian AM, Boemer F, et al. Financial cost and quality of life of patients with spinal muscular atrophy identified by symptoms or newborn screening. Dev Med Child Neurol. 2023;65(1):67\u201377.","journal-title":"Dev Med Child Neurol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03697-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03697-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03697-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T11:02:49Z","timestamp":1745492569000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03697-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,24]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3697"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03697-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,24]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by Kaohsiung Medical University Hospital (KMUH) (IRB No.: KMUHIRB-SV(II)- 20160036; IRB No. KMUHIRB-SV(II)- 20200014 and KMUHIRB-E(I)- 20240087); Chang Gung Memorial Hospital in Linkou, Taoyuan (CGMH), Taiwan (IRB No. 202202354B0); and Taipei Veterans General Hospital in Taipei (TVGH), Taiwan (IRB No. 2024-01-005A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.-H. Wang reports no disclosures relevant to the manuscript; M.-Y. Liu reports no disclosures relevant to the manuscript; L.-Y. Wang reports no disclosures relevant to the manuscript; T.-R. Hsu reports no disclosures relevant to the manuscript; I.-J. Chou has acted as a principal investigator (PI) of a clinical trial for Novartis; W.-T. Lee reports no disclosures relevant to the manuscript; H.-J. Chen reports no disclosures relevant to the manuscript; S.-M. Kao reports no disclosures relevant to the manuscript; H.-C. Ho reports no disclosures relevant to the manuscript; W.-C. Liang has acted as a Co-PI of clinical trials for Biogen, Novartis, Roche; I.-C. Lee reports no disclosures relevant to the manuscript; D.-M. Niu has acted as a PI of a clinical trial for Novartis; K.-J. Hsiao reports no disclosures relevant to the manuscript; M.-Y. Chang reports no disclosures relevant to the manuscript; H.-M. Hsieh reports no disclosures relevant to the manuscript; Y.-J. Jong has served as an advisor\/consultant for Biogen, Roche, and Novartis, acted as a PI of clinical trials for Biogen, Novartis, Roche, PTC Therapeutics, Sarepta Therapeutics, Pfizer, NS Pharma, GSK, and Eli Lilly; and obtained research grants from Biogen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"197"}}